Fox Business - The Power to Prosper
Search Site

Eli Lilly

How can investors gain from the IPO Market?

IPO Playbook Editor Tom Taulli on the opportunities in the IPO market.

Read More

  1. Lilly's Cymbalta to Trigger 'Severe' Sales Slide

    Eli Lilly (NYSE:LLY) reported fourth-quarter profit and sales declines on Thursday as patent expirations of its key depression drug Cymbalta weighed heavily on U.S. ...

  2. Eli Lilly 4Q earnings

    Earnings HQ: FBN’s Jo Ling Kent breaks down Eli Lilly ’s fourth-quarter earnings report.

  3. Bulls Charge Back: S&P Snaps 3-Day Losing Streak

    FOX Business: Capitalism Lives HereU.S. equity markets rallied, breaking a three-day losing streak, as traders cheered a round of strong data on the American economy...

  4. Wall Street Climbs on Trade Data, Yellen Optimism

    FOX Business: Capitalism Lives HereU.S. equity markets pushed higher Tuesday as traders cheered the Senate's confirmation of Janet Yellen for Fed chief and stronger-...

  5. Eli Lilly Projects In-Line '14 Profit Slump

    Mirroring forecasts from analysts, Eli Lilly (NYSE:LLY) projected a steep drop in 2014 revenue and earnings on Tuesday as the drug giant continues to grapple with th...

  6. Stock Futures Jump Amid Fed Optimism

    FOX Business: Capitalism Lives HereWall Street looked to snap a three-day slump on Tuesday after the Senate confirmed dovish Janet Yellen for the top spot at the Fed...

  7. Eli Lilly Unveils '14 Outlook and Other #Stocks2Watch

    Eli Lilly [LLY]FOX Business New Editor / Reporter Victoria Craig says she's watching shares of Eli Lilly. The pharmaceutical heavyweight revealed a 2014 outlook that...

  8. AstraZeneca to Buy Bristol's Stake in Venture

    AstraZeneca (NYSE:AZN) agreed on Thursday to buy Bristol-Myers Squibb's (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.The London-based biop...

  9. FDA to Meat Industry: Stop Using Antibiotics in Feed

    Food safety regulators said Wednesday they want food processors to begin phasing out the use of antibiotics that are fed to animals and believed harmful to humans.Th...

  10. The 'Accidental CEO': Eli Lilly's John Lechleiter

    When he began his career as a senior organic chemist in 1979, John Lechleiter had a passion for science -- chemistry was his first love -- and a desire to work in th...

  11. John Lechleiter: The ‘Accidental’ CEO

    Given the option between scientist or manager, Eli Lilly ’s chief always thought he’d pick the former. But a rare opportunity propelled him to the C-suite.

  12. NYC to form $100M venture capital fund in biotech

    NYC Economic Development Corporation president Kyle Kimball on New York City working with large pharmaceutical companies and venture capital firms to create $100M fund.

  1. Takeda, Lilly to 'Vigorously Challenge' Actos Ruling

    Takeda Pharmaceuticals and Eli Lilly (NYSE:LLY) pledged Tuesday to fight a federal court verdict ordering them to pay a combined $9 billion after a jury ruled the tw...

  2. Wyndham Eyed on Cyber Case Decision and Other #Stocks2Watch

    Wyndham Worldwide (NYSE:WYN)Wyndham Worldwide (NYSE:WYN) shares will be in focus after a federal judge ruled the Federal Trade Commission can continue in its cyber-s...

  3. Pfizer shares down despite positive news on breast cancer drug

    FBN’s Nicole Petallides on the highlights from the day in the markets.

  4. Lilly Expands Generic Deal With Prasco

    Eli Lilly (NYSE:LLY) expanded a generic drug agreement on Tuesday that enables Prasco to market a generic version of Lilly's osteoporosis treatment Evista in the U.S...

  5. April stock picks

    Janney chief investment strategist Mark Luschini gives his outlook for the markets.

  6. Merck Snags Baxter Executive As CFO

    Merck (NYSE:MRK) tapped Baxter (NYSE:BAX) executive Robert Davis on Thursday to replace current finance head Peter Kellogg as the company struggles to revive sales a...

  7. Zale Shares Sparkle and Other #Stocks2Watch

    Zale [ZLC]Signet Jewelers said it will buy competitor Zale for $690 million. The move is sending Zale shares surging some 30%, while Signet is up 6%. Full Quote http...

‹ Prev12345Next ›
Freebase CC-BY
Source: Eli Lilly on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL